Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Glioblastoma 12Prostatic Neoplasms 11Oropharyngeal Neoplasms 10Lung Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 9Glioma 8Urinary Bladder Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Esophageal Neoplasms 6Neoplasm Metastasis 5Mouth Neoplasms 5Carcinoma 5Burkitt Lymphoma 5Astrocytoma 5Sarcoma 4Pancreatic Neoplasms 4Laryngeal Neoplasms 4Gliosarcoma 4Carcinoma, Hepatocellular 4Brain Neoplasms 4Adenocarcinoma of Lung 4Adenocarcinoma Of Esophagus 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Rhabdomyosarcoma, Embryonal 3Rhabdomyosarcoma 3Rectal Neoplasms 3Neoplasms 3

Interventions

relugolix 2acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2Specimen Handling 2Radiotherapy 2Radiation 2Magnetic Resonance Spectroscopy 2Leuprolide 2Goserelin 2Biopsy 2radium Ra 223 dichloride 1luprolide acetate gel depot 1histrelin 1gallium 68 PSMA-11 1enzalutamide 1darolutamide 1bicalutamide 1Triptorelin Pamoate 1Surgical Procedures, Operative 1Salicylic Acid 1Radiotherapy, Image-Guided 1Radiosurgery 1Radiation Dose Hypofractionation 1Flutamide 1Buserelin 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostate Adenocarcinoma × Radiation × 90 days × Clear all
NCT03274687 2026-05-20

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

NRG Oncology

Phase 3 Completed
296 enrolled 29 charts
Genitourinary

Prostate Adenocarcinoma

NCT05050084 2026-05-04

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NRG Oncology

Phase 3 Active not recruiting
2,050 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡